Restricted accessReview articleFirst published online 2018-10
The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials
The aim of this study was to assess the efficacy and safety of stimulant and nonstimulant medications in children and adolescents using as an outcome measure the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV), and to examine the effect of medications in different ADHD subtypes (i.e., inattention and hyperactivity/impulsivity).
Methods:
MEDLINE, Scopus, EMBASE, EBSCO (E-journal, CINAHL and SportDiscus), PUBMED, and The Cochrane Central Register of Controlled Trials databases were searched. Randomized controlled trials (RCTs) with parallel group or placebo-controlled studies comparing the effect of medications (stimulants or nonstimulants) in children and adolescents with ADHD were included. The main outcomes were the ADHD-RS-IV total score and subtypes (inattention and hyperactivity/impulsivity). Treatment-emergent adverse events (TEAEs) and secondary outcomes such as systolic and diastolic blood pressure, and pulse rate were considered.
Results:
The search strategy identified 15 RCTs, including a total of 4648 children and/or adolescents diagnosed with ADHD aged 6 to 17 years old. Overall, both stimulant and nonstimulant medications reduce the ADHD-RS-IV score with a standardized mean difference (SMD) of −0.70 (confidence interval [95% CI], −0.85 to −0.55); in subgroup analyses, the SMD was −0.83 (95% CI, −1.11 to −0.54) for stimulant medications and −0.58 (95% CI, −0.69 to −0.46) for nonstimulant medications. Similar results were observed in inattention and hyperactivity/impulsivity subtypes. The placebo group also showed a medium effect SMD of −0.68 (95% CI, −0.82 to −0.54). The most frequent TEAEs for stimulant and nonstimulant medications, respectively, were decreased appetite (28.6% and 14.2%) and somnolence (4.4% and 34.1%).
Conclusions:
These results suggest that both stimulant and nonstimulant medications mitigate ADHD symptoms in children and adolescents, although subgroup analyses suggest a greater effectiveness of stimulant medications.
Get full access to this article
View all access options for this article.
References
1.
AchenbachTM: Integrative Guide for the 1991 CBCL/4-18, YSR and TRF Profiles. Burlington, VT, University of Vermont, 1991.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Revised Text (DSM-IV-RT), 4th ed. Washington, DC: American Psychiatric Association, 2002.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
BiedermanJ, KrishnanS, ZhangY, McGoughJJ, FindlingRL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther, 29:450–463, 2007.
9.
BiedermanJ, MelmedRD, PatelA, McBurnettK, KonowJ, LyneA, Scherer N; SPD503 StudyGroup: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121:e73–e84, 2008.
10.
Catala-LopezF, HuttonB, Nunez-BeltranA, MayhewAD, PageMJ, RidaoM, TobiasA, CatalaMA, Tabares-SeisdedosR, MoherD: The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Protocol for a systematic review and network meta-analysis of randomized controlled trials. Syst Rev, 4:19, 2015.
11.
ChanE, FoglerJM, HammernessPG: Treatment of attention-deficit/hyperactivity disorder in adolescents: A systematic review. JAMA, 315:1997–2008, 2016.
12.
CharachA, IckowiczA, SchacharR: Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry, 43:559–567, 2004.
13.
ChildressAC, ArnoldV, AdeyiB, DirksB, BabcockT, SchecknerB, LasserR, LopezFA: The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord, 18:123–132, 2014.
14.
CoghillD, BanaschewskiT, LecendreuxM, SoutulloC, JohnsonM, ZuddasA, AndersonC, CivilR, HigginsN, LyneA, SquiresL: European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol, 23:1208–1218, 2013.
15.
CoghillDR, BanaschewskiT, LecendreuxM, ZuddasA, DittmannRW, OteroIH, CivilR, BloomfieldR, SquiresLA: Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: Results from a randomized, controlled trial. Eur Child Adolesc Psychiatry, 23:61–68, 2014.
16.
CohenJ: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, L Erlbaum Associates, 1988.
ConnorDF, FindlingRL, KollinsSH, SalleeF, LopezFA, LyneA, TremblayG: Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs, 24:755–768, 2010.
19.
DupaulGJ, PowerTJ, AnastopoulosAD, ReidR: ADHD Rating Scale IV (for Children and Adolescents): Checklist, Norms, and Clinical Interpretation. New York, NY, Guilford Press, 1998.
20.
EggerM, SmithGD, SchneiderM, MinderC: Bias in meta-analysis detected by a simple, graphical test. BMJ, 315:629–634, 1997.
21.
FaraoneSV: Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T, 34:678–694, 2009.
22.
FaraoneSV, BiedermanJ, SpencerT, WilensT, SeidmanLJ, MickE, DoyleAE: Attention-deficit/hyperactivity disorder in adults: An overview. Biol Psychiatry, 48:9–20, 2000.
23.
FaraoneSV, SergeantJ, GillbergC, BiedermanJ: The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry, 2:104–113, 2003.
24.
FayyadJ, De GraafR, KesslerR, AlonsoJ, AngermeyerM, DemyttenaereK, De GirolamoG, HaroJM, KaramEG, LaraC, LepineJP, OrmelJ, Posada-VillaJ, ZaslavskyAM, JinR: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry, 190:402–409, 2007.
25.
FindlingRL, BuksteinOG, MelmedRD, LopezFA, SalleeFR, ArnoldLE, PrattRD: A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 69:149–159, 2008.
26.
FindlingRL, ChildressAC, CutlerAJ, GasiorM, HamdaniM, Ferreira-CornwellMC, SquiresL: Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 50:395–405, 2011.
27.
FindlingRL, TurnbowJ, BurnsideJ, MelmedR, CivilR, LiY: A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr, 15:419–430, 2010.
28.
GrahamJ, BanaschewskiT, BuitelaarJ, CoghillD, DanckaertsM, DittmannRW, DopfnerM, HamiltonR, HollisC, HoltmannM, Hulpke-WetteM, LecendreuxM, RosenthalE, RothenbergerA, SantoshP, SergeantJ, SimonoffE, Sonuga-BarkeE, WongIC, ZuddasA, SteinhausenHC, Taylor E; European GuidelinesGroup: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry, 20:17–37, 2011.
29.
GuyattGH, OxmanAD, KunzR, VistGE, Falck-YtterY, Schunemann HJ; GRADE WorkingGroup: What is “quality of evidence”. and why is it important to clinicians? BMJ, 336:995–998, 2008.
30.
HervasA, HussM, JohnsonM, McNicholasF, van StralenJ, SreckovicS, LyneA, BloomfieldR, SikiricaV, RobertsonB: Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, phase III trial. Eur Neuropsychopharmacol, 24:1861–1872, 2014.
31.
HigginsJP, AltmanDG, GotzschePC, JuniP, MoherD, OxmanAD, SavovicJ, SchulzKF, WeeksL, SterneJA, Cochrane Bias Methods G; Cochrane Statistical MethodsGroup: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343:d5928, 2011.
32.
HigginsJP, GreenS: Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
33.
HorwitzRI, HorwitzSM: Adherence to treatment and health outcomes. Arch Intern Med, 153:1863–1868, 1993.
34.
HrobjartssonA, KaptchukTJ, MillerFG: Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol, 64:1223–1229, 2011.
35.
JainR, SegalS, KollinsSH, KhayrallahM: Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 50:171–179, 2011.
36.
KesslerRC, AdlerL, BarkleyR, BiedermanJ, ConnersCK, DemlerO, FaraoneSV, GreenhillLL, HowesMJ, SecnikK, SpencerT, UstunTB, WaltersEE, ZaslavskyAM: The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry, 163:716–723, 2006.
37.
KienleGS, KieneH: Placebo effect and placebo concept: A critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med, 2:39–54, 1996.
38.
KolarD, KellerA, GolfinopoulosM, CumynL, SyerC, HechtmanL: Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat, 4:389–403, 2008.
39.
LoneyJ, PrinzRJ, MishalowJ, JoadJ: Hyperkinetic/aggressive boys in treatment: Predictors of clinical response to methylphenidate. Am J Psychiatry, 135:1487–1491, 1978.
40.
MaybergHS, SilvaJA, BrannanSK, TekellJL, MahurinRK, McGinnisS, JerabekPA: The functional neuroanatomy of the placebo effect. Am J Psychiatry, 159:728–737, 2002.
41.
McCarthyS, WiltonL, MurrayML, HodgkinsP, AshersonP, WongIC: The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr, 12:78, 2012.
42.
McGoeyK, DuPaulG, HaleyE, SheltonTL: Parent and teacher ratings of attention-deficit/hyperactivity disorder in preschool: The ADHD Rating Scale-IV preschool version. J Psychopathol Behav Assess 29 26, 9–276, 2007.
43.
NewcornJH, SteinMA, ChildressAC, YouchaS, WhiteC, EnrightG, RubinJ: Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: Morning or evening administration. J Am Acad Child Adolesc Psychiatry, 52:921–930, 2013.
44.
NICE: The National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults: NICE guideline, 2008.
45.
PliszkaSR, CrismonML, HughesCW, CornersCK, EmslieGJ, JensenPS, McCrackenJT, SwansonJM, Lopez M; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit HyperactivityDisorder: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 45:642–657, 2006.
46.
PolanczykG, de LimaMS, HortaBL, BiedermanJ, RohdeLA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry, 164:942–948, 2007.
47.
SalleeFR, McGoughJ, WigalT, DonahueJ, LyneA, Biederman J; SPD503 STUDYGROUP: Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48:155–165, 2009.
48.
SandlerAD, GlesneCE, BodfishJW: Conditioned placebo dose reduction: A new treatment in attention-deficit hyperactivity disorder?. J Dev Behav Pediatr, 31:369–375, 2010.
49.
SavovicJ, WeeksL, SterneJA, TurnerL, AltmanDG, MoherD, HigginsJP: Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: Focus groups, online survey, proposed recommendations and their implementation. Syst Rev, 3:37, 2014.
50.
SchwartzS, CorrellCU: Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry, 53:174–187, 2014.
51.
SibleyMH, KuriyanAB, EvansSW, WaxmonskyJG, SmithBH: Pharmacological and psychosocial treatments for adolescents with ADHD: An updated systematic review of the literature. Clin Psychol Rev, 34:218–232, 2014.
52.
SpencerTJ, WilensTE, BiedermanJ, WeislerRH, ReadSC, PrattR: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 28:266–279, 2006.
53.
StuhecM, LukicP, LocatelliI: Comparative efficacy of lisdexamfetamine, mixed amphetamine salts and methylphenidate in treatment of attention deficit hyperactivity disorder in adults: A systematic review and meta-analysis. Eur Neuropsychopharmacol, S446:26, 2016.
54.
StuhecM, MundaB, SvabV, LocatelliI: Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion. J Affect Disord, 178:149–159, 2015.
55.
TakahashiM, TakitaY, YamazakiK, HayashiT, IchikawaH, KambayashiY, KoedaT, OkiJ, SaitoK, TakeshitaK, AllenAJ: A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 19:341–350, 2009.
56.
WaschbuschDA, PelhamWEJr., WaxmonskyJ, JohnstonC: Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?. J Dev Behav Pediatr, 30:158–168, 2009.
57.
WigalSB, KollinsSH, ChildressAC, SquiresL, StudyG: A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health, 3:17, 2009.
58.
WilensTE, BiedermanJ: The stimulants. Psychiatr Clin North Am, 15:191–222, 1992.
59.
WilensTE, RobertsonB, SikiricaV, HarperL, YoungJL, BloomfieldR, LyneA, RynkowskiG, CutlerAJ: A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 54:916–925.e2, 2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
